Avoro Capital Advisors LLC 4

What Happened
Behzad Aghazadeh, reported as a 10% owner (via Avoro Capital Advisors/Avoro Ventures), was granted a derivative award covering 38,040 shares of Whitehawk Therapeutics (WHWK) on June 12, 2026. The reported acquisition price is $0.00, and the grant is reported as a derivative (an option-type award per the filing). This is an award/grant (not an open-market purchase or sale).

Key Details

• Transaction date: June 12, 2026; Form 4 filed June 15, 2026.
• Transaction type/code: A (Grant / award / other acquisition); derivative instrument covering 38,040 shares; price reported $0.00.
• Vesting: Per footnote, 100% of the shares subject to the option vest on the earlier of (i) one year after the June 12, 2026 grant date or (ii) the day before the next annual meeting, provided the Reporting Person remains a Service Provider under the 2021 Equity Incentive Plan.
• Shares owned after transaction: Not specified in this filing.
• Reporting parties: Filed by Avoro Capital Advisors LLC, Avoro Ventures LLC and Behzad Aghazadeh; Dr. Aghazadeh serves as portfolio manager/controlling person of the Avoro entities. Footnote disclaimers state the Reporting Persons disclaim beneficial ownership except to the extent of pecuniary interest.
• Filing timeliness: Form 4 was filed three days after the grant (June 15 vs. June 12); the filing does not indicate a late filing code.

Context
This was a derivative grant (option-like award) subject to service-based vesting rather than an immediate purchase or sale. Because the reporting parties include Avoro investment entities and Dr. Aghazadeh is a 10% owner and portfolio manager, this filing reflects institutional/insider-affiliated awarding rather than typical executive open-market buying or selling. The award vests on a short schedule (up to one year) if service conditions are met; the filing gives no cash value or post-transaction total ownership figure.